SynthesisFrontiers in immunology2026
Global research trends and focus on biomarkers in lung cancer immunotherapy: a comprehensive bibliometric insight and visualization analysis (2001-2025).
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Exercise-mediated extracellular vesicle-derived non-coding RNAs and cardiovascular protection: mechanistic insights and bibliometric analysis.Frontiers in physiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy has revolutionized the therapeutic paradigm for lung cancer, yet its clinical efficacy exhibits significant interpatient heterogeneity. The implementation of personalized immunotherapy critically depends on the precise identification of predictive biomarkers. However, this field is currently characterized by rapid expansion of research outputs alongside marked fragmentation of knowledge domains, while a systematic evaluation of scientific advancements and emerging frontiers remains conspicuously absent. This study aims to synthesize global research achievements to methodologically delineate the evolutionary trajectory of immunotherapy biomarkers in lung cancer, identify research hotspots, and forecast developmental trends. Methods: A bibliometric analysis was conducted on 6,180 publications (2001-2025) from the Web of Science Core Collection. Advanced tools (Bibliometrix, VOSviewer, CiteSpace) were employed to analyze publication trends, country/institutional contributions, journal influence, author networks, keyword evolution, and citation dynamics. Results: The field progressed through incubation (2003-2014), rapid expansion (2015-2022), and maturation (2023-2025) phases, with a 28.87% annual growth rate. China led in productivity (9,394 publications), while the U.S. dominated academic impact (93,888 citations). Harvard University Harvard University emerged as the predominant contributor (532 publications). WANG Y was ranked first in the top 10 most prolific authors (97 publications) while RAMALINGAM SS (5,033 citations) was the most cited authors. CANCERS (319 papers; Q1) was the most published journal, while JOURNAL FOR IMMUNOTHERAPY OF CANCER (8,511 citations; Q1) was the most cited journal. Emerging frontiers encompassed genomics, gut microbiome, soluble PD-L1, and immune infiltration patterns, driven by multi-omics integration and artificial intelligence. Conclusion: This study represents the first bibliometric analysis of biomarkers in lung cancer immunotherapy. Through scientometric visualization tools, our analysis delineates a paradigm shift from reductionist biomarker discovery to multidimensional integration and translational validation. Prospective advancements necessitate leveraging technological innovations, fostering international collaborative networks, and promoting multi-omics convergence. These efforts aim to facilitate a critical transition from population-based therapeutic strategies to precision-driven stratification, ultimately optimizing clinical outcomes and survival benefits for heterogeneous patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.